Tumor Necrosis Factor-α, Fecal Calprotectin, and Disease Activity in Inflammatory Bowel Disease Patients

Christian Syukur; Bradley Jimmy Waleleng; Fandy Gosal; Luciana Sophie Mariana Rotty; Jeanne Winarta; Andrew Waleleng

doi:10.3889/oamjms.2023.11284

Authors

Christian Syukur Department of Internal Medicine, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia https://orcid.org/0000-0003-1385-9247
Bradley Jimmy Waleleng Department of Internal Medicine, Division of Gastroenterology-Hepatology, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Fandy Gosal Department of Internal Medicine, Division of Gastroenterology-Hepatology, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Luciana Sophie Mariana Rotty Department of Internal Medicine, Division of Gastroenterology-Hepatology, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Jeanne Winarta Department of Internal Medicine, Division of Gastroenterology-Hepatology, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia
Andrew Waleleng Department of Internal Medicine, Division of Gastroenterology-Hepatology, Faculty of Medicine, Universitas Sam Ratulangi, Prof. Dr. R. D. Kandou Hospital, Manado, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2023.11284

Keywords:

IBD, TNF-α, Fecal calprotectin, Disease activity

Abstract

INTRODUCTION: Inflammatory bowel disease (IBD) has increased incidence and the lack of effective long-term therapeutic options has resulted in mortality from intestinal complications and also significant costs to the country’s health-care system. Evaluation of disease activity in IBD patients is beneficial for establishing clinical judgments, especially in giving therapy and knowing the response of the given therapy. Tumor necrosis factor (TNF)-α, fecal calprotectin (FC), Lichtiger index, and Crohn’s Disease Endoscopic Index of Severity (CDEIS) are useful tools for evaluating disease activity. This study wants to know the relationship between biomarkers with disease activity.

METHODS: A cross-sectional retrospective study was conducted on IBD patients. The diagnosis of IBD was based on findings from the gastrointestinal tract during colonoscopy and biopsy that showed features of IBD. TNF-α _was taken from the patient’s serum, while FC was from the patient’s stool sample. Lichtiger index was taken from anamneses, while CDEIS from endoscopy. The data will be analyzed using SPSS 22.0.

RESULTS: A total of 35 patients with IBD met the inclusion criteria. This study found a 0.7-fold risk in IBD patients to have moderate-severe activity if they had TNF-α _levels of ≥ 1.14 pg/mL, although it was not significant (p = 0.581; OR:0.68; 95%CI 0.18-2.66). A significant relationship was found in the value of FC with disease activity in IBD patients, with a six-fold risk of having IBD with moderate-to-severe activity if FC levels ≥254 μg/g (p=0,011, OR:6,24, 95%CI 1,44-27,06).

CONCLUSION: Fecal calprotectin levels have significant relationship with disease activity in IBD patients, both clinically and endoscopically. Fecal calprotectin is a decent marker for assessing disease activity in IBD patients.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. https://doi.org/10.1038/s41572-020-0205-x PMid:32913180 DOI: https://doi.org/10.1038/s41572-020-0205-x

Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489-526. https://doi.org/10.1007/s00535-021-01784-1 PMid:33885977 DOI: https://doi.org/10.1007/s00535-021-01784-1

Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390(10114):2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0 PMid:29050646 DOI: https://doi.org/10.1016/S0140-6736(17)32448-0

Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019;94(7):1357-73. https://doi.org/10.1016/j.mayocp.2019.01.018 PMid:31272578 DOI: https://doi.org/10.1016/j.mayocp.2019.01.018

Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43-8. https://doi.org/10.1016/j.cgh.2012.09.026 PMid:23022699 DOI: https://doi.org/10.1016/j.cgh.2012.09.026

Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting inflammatory bowel disease: pathology, treatments, challenges and emerging therapeutics including drug leads from natural products. J Clin Med. 2020;9(5):1273. https://doi.org/10.3390/jcm9051273 PMid:32354192 DOI: https://doi.org/10.3390/jcm9051273

Saha A, Tighe MP, Batra A. How to use faecal calprotectin in management of paediatric inflammatory bowel disease. Arch Dis Child Educ Pract Ed. 2016;101(3):124-8. https://doi.org/10.1136/archdischild-2014-307941 PMid:26848103 DOI: https://doi.org/10.1136/archdischild-2014-307941

Yui S, Nakatani Y, Hunter MJ, Chazin WJ, Yamazaki M. Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity. Mediators Inflamm. 2002;11(3):165-72. https://doi.org/10.1080/09622935020138208 PMid:12137245 DOI: https://doi.org/10.1080/09622935020138208

Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol. 2014;20(2):363-75. https://doi.org/10.3748/wjg.v20.i2.363 PMid:24574706 DOI: https://doi.org/10.3748/wjg.v20.i2.363

Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330(26):1841-5. https://doi.org/10.1056/NEJM199406303302601 PMid:8196726 DOI: https://doi.org/10.1056/NEJM199406303302601

Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13(10):567-79. https://doi.org/10.1038/nrgastro.2016.128 PMid:27580684 DOI: https://doi.org/10.1038/nrgastro.2016.128

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: Clinical aspects and treatments. J Inflamm Res. 2014;7(1):113-20. https://doi.org/10.2147/JIR.S65979 PMid:25075198 DOI: https://doi.org/10.2147/JIR.S65979

Nakov RV, Nakov VN, Gerova VA, Penchev PI, Tankova L, Kundurzhiev TG. Correlation between ulcerative colitis endoscopic index of severity, Lichtiger index and fecal calprotectin in ulcerative colitis patients. Intern Med Open Access. 2017;7(4):248. https://doi.org/10.4172/2165-8048.1000248 DOI: https://doi.org/10.4172/2165-8048.1000248

Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn’s disease: Monitoring disease activity. Aliment Pharmacol Ther. 2003;17 suppl 2:11-7. https://doi.org/10.1046/j.1365-2036.17.s2.17.x PMid:12786607 DOI: https://doi.org/10.1046/j.1365-2036.17.s2.17.x

Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. World J Gastroenterol. 2014;20(33):11525-37. https://doi.org/10.3748/wjg.v20.i33.11525 PMid:25206259 DOI: https://doi.org/10.3748/wjg.v20.i33.11525

Barreto ID, Carmona R, Díaz F, Marín-Jiménez I. Prevalence and demographic characteristics of inflammatory bowel disease in Cartagena, Colombia. Rev Colomb Gastroenterol. 2010;25(2):107-11.

Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: A prospective longitudinal cohort study. J Clin Gastroenterol. 2018;52(3):229-34. https://doi.org/10.1097/MCG.0000000000000774 PMid:27984399 DOI: https://doi.org/10.1097/MCG.0000000000000774

Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and west differences. J Dig Dis. 2007;8(3):121-7. https://doi.org/10.1111/j.1443-9573.2007.00296.x PMid:17650222 DOI: https://doi.org/10.1111/j.1443-9573.2007.00296.x

Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JG. Review: Local tumor necrosis factor-α inhibition in inflammatory bowel disease. Pharmaceutics. 2020;12(6):539. https://doi.org/10.3390/pharmaceutics12060539 PMid:32545207 DOI: https://doi.org/10.3390/pharmaceutics12060539

Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004;99(8):1532-8. https://doi.org/10.1111/j.1572-0241.2004.30432.x PMid:15307873 DOI: https://doi.org/10.1111/j.1572-0241.2004.30432.x

Brannigan AE, OʼConnell RP, Hurley H, O’Neill A, Brady HR, Fitzpatrick FM, et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock. 2000;13(5):361-6. https://doi.org/10.1097/00024382-200005000-00003 PMid:10807010 DOI: https://doi.org/10.1097/00024382-200005000-00003

Bertani L, Mumolo MG, Tapete G, Albano E, Svizzero GB, Zanzi F, et al. Fecal calprotectin: Current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol. 2020;32(9):1091-8. https://doi.org/10.1097/MEG.0000000000001731 PMid:32282400 DOI: https://doi.org/10.1097/MEG.0000000000001731

Tan J, Subramaniam K, Neeman T. Utility of serum anti-tumor necrosis factor levels and biomarkers in predicting endoscopic disease activity and clinical remission in inflammatory bowel disease. J Gastroenterol Hepatol. 2020;13(2):53-8. https://doi.org/10.15406/ghoa.2022.13.00494 DOI: https://doi.org/10.15406/ghoa.2022.13.00494

D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218-24. https://doi.org/10.1002/ibd.22917 PMid:22344983 DOI: https://doi.org/10.1002/ibd.22917

Molander P, Af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011-7. https://doi.org/10.1002/ibd.22863 PMid:22223566 DOI: https://doi.org/10.1002/ibd.22863

Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39(10):1017-20. https://doi.org/10.1080/00365520410007971 PMid:15513345 DOI: https://doi.org/10.1080/00365520410007971

Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22. https://doi.org/10.1053/gast.2000.8523 PMid:10889150 DOI: https://doi.org/10.1053/gast.2000.8523

Dragoni G, Innocenti T, Galli A. Biomarkers of inflammation in inflammatory bowel disease: How long before abandoning single-marker approaches? Dig Dis. 2021;39(3):190-203. https://doi.org/10.1159/000511641 PMid:32942275 DOI: https://doi.org/10.1159/000511641

Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(5):1275-85.e2. https://doi.org/10.1053/j.gastro.2015.07.003 PMid:26166315 DOI: https://doi.org/10.1053/j.gastro.2015.07.003